A Bivalent Human Norovirus Vaccine Induces Homotypic and Heterotypic Neutralizing Antibodies
A GII.2 outbreak in an efficacy study of a bivalent virus-like particle norovirus vaccine, TAK-214, in healthy US adults provided an opportunity to examine GII.4 homotypic vs GII.2 heterotypic responses to vaccination and infection. Three serologic assays-virus-like particle binding, histoblood group antigen blocking, and neutralizing-were performed for each genotype. Results were highly correlated within a genotype but not between genotypes. Although the vaccine provided protection from GII.2-associated disease, little GII.2-specific neutralization occurred after vaccination. Choice of antibody assay can affect assessments of human norovirus vaccine immunogenicity.
Authors
- Amanda Brinkman (ORCID: https://orcid.org/0000-0002-2845-6494)
- Robert L. Atmar (ORCID: https://orcid.org/0000-0001-9989-6772)
- Frederick H. Neill (ORCID: https://orcid.org/0000-0001-7792-3135)
- Ralph Steven Baric (ORCID: https://orcid.org/0000-0001-6827-8701)
- Khalil Ettayebi (ORCID: https://orcid.org/0000-0003-3011-4693)
- Ralph P. Braun (ORCID: https://orcid.org/0000-0003-1253-8206)
- Lisa C. Lindesmith (ORCID: https://orcid.org/0000-0001-9567-0522)
- James Sherwood (ORCID: https://orcid.org/0009-0005-3448-4829)
- Sasirekha Ramani (ORCID: https://orcid.org/0000-0001-5631-8534)
- Mary Kolb Estes (ORCID: https://orcid.org/0000-0002-4813-4249)
Institutions
- University of North Carolina at Chapel Hill (US)
Publication Details
- Journal
- Carolina Digital Repository (University of North Carolina at Chapel Hill)
- Published
- 2024-12-21
- DOI
- https://doi.org/10.17615/4g00-sy60
- Primary Topic
- Viral gastroenteritis research and epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00